Literature DB >> 20230546

Populating an economic model with health state utility values: moving toward better practice.

Roberta Ara1, John E Brazier.   

Abstract

BACKGROUND: The methods used to estimate health-state utility values (HSUV) for multiple health conditions can produce very different values. Economic results generated using baselines of perfect health are not comparable with those generated using baselines adjusted to reflect the HSUVs associated with the health condition. Despite this, there is no guidance on the preferred techniques and little research describing the effect on cost per quality adjusted life-year (QALY) results when using the different methods.
METHODS: Using a cardiovascular disease (CVD) model and cost per QALY thresholds, we assess the consequence of using different baseline health-state utility profiles (perfect health, no history of CVD, general population) in conjunction with models (minimum, additive, multiplicative) frequently used to approximate scores for health states with multiple health conditions. HSUVs are calculated using the EQ-5D UK preference-based algorithm.
RESULTS: Assuming a baseline of perfect health ignores the natural decline in quality of life associated with age, overestimating the benefits of treatment. The results generated using baselines from the general population are comparable to those obtained using baselines from individuals with no history of CVD. The minimum model biases results in favor of younger-aged cohorts. The additive and multiplicative models give similar results.
CONCLUSION: Although further research in additional health conditions is required to support our findings, our results highlight the need for analysts to conform to an agreed reference case. We demonstrate that in CVD, if data are not available from individuals without the health condition, HSUVs from the general population provide a reasonable approximation.

Entities:  

Mesh:

Year:  2010        PMID: 20230546     DOI: 10.1111/j.1524-4733.2010.00700.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  77 in total

1.  The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty.

Authors:  H Dakin; P Eibich; D Beard; A Gray; A Price
Journal:  Bone Joint J       Date:  2020-07       Impact factor: 5.082

2.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

3.  Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation.

Authors:  Juliet Hounsome; Gerlinde Pilkington; James Mahon; Angela Boland; Sophie Beale; Eleanor Kotas; Tara Renton; Rumona Dickson
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

Review 4.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

5.  Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT.

Authors:  Rebecca Palmer; Munyaradzi Dimairo; Nicholas Latimer; Elizabeth Cross; Marian Brady; Pam Enderby; Audrey Bowen; Steven Julious; Madeleine Harrison; Abualbishr Alshreef; Ellen Bradley; Arjun Bhadhuri; Tim Chater; Helen Hughes; Helen Witts; Esther Herbert; Cindy Cooper
Journal:  Health Technol Assess       Date:  2020-04       Impact factor: 4.014

Review 6.  Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.

Authors:  Laura T Burgers; William K Redekop; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

7.  Association between knee symptoms, change in knee symptoms over 6-9 years, and SF-6D health state utility among middle-aged Australians.

Authors:  Ambrish Singh; Julie A Campbell; Alison Venn; Graeme Jones; Leigh Blizzard; Andrew J Palmer; Terence Dwyer; Flavia Cicuttini; Changhai Ding; Benny Antony
Journal:  Qual Life Res       Date:  2021-05-03       Impact factor: 4.147

Review 8.  Estimating Health State Utility Values for Comorbidities.

Authors:  Roberta Ara; John Brazier
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

9.  Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation.

Authors:  Philip Riley; Anne-Marie Glenny; Helen V Worthington; Elisabet Jacobsen; Clare Robertson; Justin Durham; Stephen Davies; Helen Petersen; Dwayne Boyers
Journal:  Health Technol Assess       Date:  2020-02       Impact factor: 4.014

Review 10.  Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.

Authors:  Lesley Uttley; Ben Kearns; Shijie Ren; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.